1 Event Eli Lilly Investors Must Watch

A look at three of the most important drugs in diabetes.

Max Macaluso
Max Macaluso
Feb 15, 2013 at 6:30PM
Health Care

Eli Lilly's (NYSE:LLY) mealtime insulin product Humalog brought in a whopping $2.4 billion last year. This drug comprises more than 10% of the drugmaker's total revenue, but Humalog's longevity could be compromised by an upcoming patent expiration, stiff competition by diabetes specialist Novo Nodisk (NYSE:NVO), and more competition in the future if MannKind (NASDAQ:56400P706) can get Afrezza, an ultra-rapid and inhalable insulin, on the market. In this video, health-care analyst Max Macaluso dives into this drug's sales, and breaks down the competitive landscape for investors.